<p>Pacira BioSciences（納斯達克股票代碼：PCRX - 獲取免費報告）在週一向投資者發佈的研究報告中被巴克萊的股票分析師上調至 “持有” 評級，Zacks.com 報道。</p>
<p>獲取 <strong>Pacira BioSciences</strong> 的提醒：</p>
<p>PCRX 已成為其他多份報告的主題。華爾街禪在 11 月 8 日的研究報告中將 Pacira BioSciences 的股票評級從 “買入” 上調至 “強力買入”。HC Wainwright 在 11 月 17 日的報告中重申了 “買入” 評級，並對 Pacira BioSciences 的股票設定了 38.00 美元的目標價。Truist Financial 在 11 月 7 日的研究報告中將 Pacira BioSciences 的股票目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “買入” 評級。Weiss Ratings 在週一的報告中重申了 Pacira BioSciences 的 “賣出（d+）” 評級。最後，Zacks Research 在 8 月 14 日的研究報告中將 Pacira BioSciences 的評級從 “強烈賣出” 上調至 “持有”。三位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價為 28.20 美元。</p>
<p><strong>查看我們最新的 Pacira BioSciences 股票報告</strong></p>
<h2>Pacira BioSciences 股票表現</h2>
<p>納斯達克股票代碼：PCRX 的股票在週一開盤價為 24.77 美元。該公司的流動比率為 5.26，速動比率為 3.78，債務與股本比率為 0.52。Pacira BioSciences 的 1 年最低價為 18.17 美元，1 年最高價為 27.64 美元。該股票的市值為 10.7 億美元，市盈率為 55.05，貝塔值為 0.23。該公司的 50 日移動平均價格為 23.09 美元，200 日移動平均價格為 24.13 美元。</p>
<p>Pacira BioSciences（納斯達克股票代碼：PCRX - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.70 美元，超出市場共識預期的 0.65 美元，超出幅度為 0.05 美元。Pacira BioSciences 的淨利潤率為 2.99%，股本回報率為 12.82%。該公司本季度的收入為 1.7952 億美元，而分析師預期為 1.8286 億美元。去年同期，該公司每股收益為 0.79 美元。該公司的季度收入同比增長 6.5%。股票分析師預測 Pacira BioSciences 在本年度將發佈 2.41 美元的每股收益。</p>
<h2>Pacira BioSciences 的內部交易</h2>
<p>在其他 Pacira BioSciences 的新聞中，內部人士 Jonathan Slonin 在 11 月 17 日的交易中出售了 3,960 股 Pacira BioSciences 的股票。該股票以平均價格 24.09 美元出售，總價值為 95,396.40 美元。出售後，該內部人士持有該公司 178,367 股股票，價值為 4,296,861.03 美元。此交易代表其持股比例下降了 2.17%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。公司內部人士持有該公司 6.40% 的股票。</p>
<h2>機構投資者對 Pacira BioSciences 的看法</h2>
<p>機構投資者最近買入和賣出了該公司的股票。Alyeska Investment Group L.P.在第一季度購買了 Pacira BioSciences 的新頭寸，金額約為 32,506,000 美元。Doma Perpetual Capital Management LLC 在第三季度將其在 Pacira BioSciences 的持倉提高了 49.7%。Doma Perpetual Capital Management LLC 現在擁有該公司 2,701,324 股股票，價值 69,613,000 美元，此前在上個季度又購買了 897,255 股。Balyasny Asset Management L.P.在第二季度將其在 Pacira BioSciences 的持倉提高了 36.1%。Balyasny Asset Management L.P.現在擁有該公司 2,130,733 股股票，價值 50,925,000 美元，此前在上個季度又購買了 565,288 股。American Century Companies Inc.在第一季度將其在 Pacira BioSciences 的持倉提高了 392.2%。American Century Companies Inc.現在擁有該公司 667,423 股股票，價值 16,585,000 美元，此前在上個季度又購買了 531,831 股。最後，Nuveen LLC 在第一季度購買了 Pacira BioSciences 的新頭寸，價值為 12,884,000 美元。機構投資者持有該公司 99.73% 的股票。</p>
<h2>Pacira BioSciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Pacira Biosciences, Inc 是一家控股公司，專注於提供非阿片類疼痛管理和再生健康解決方案，以改善患者在神經疼痛路徑上的體驗。其產品包括 EXPAREL、iovera 和 DepoFoam。該公司成立於 2006 年 12 月，總部位於佛羅里達州坦帕。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Pacira BioSciences</li>
<li>如何交易便士股票：逐步指南</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>3 只家居改善股票可以升級你的投資組合</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年爆發</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>安海斯 - 布希收購 BeatBox 以贏得年輕飲酒者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Pacira BioSciences 嗎？</h2>
<p>在考慮 Pacira BioSciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Pacira BioSciences 並不在名單上。</p>
<p>雖然 Pacira BioSciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Pacira制藥

<p>巴克萊將 Pacira BioSciences（NASDAQ:PCRX）的評級上調至 “持有”。其他分析師的評級各不相同：華爾街禪將其評級上調至 “強力買入”，HC Wainwright 維持 “買入” 評級，目標價為 38 美元，Truist Financial 將目標價下調至 28 美元但保持 “買入” 評級，Weiss Ratings 重申 “賣出” 評級，Zacks Research 則上調至 “持有”。該股票以 24.77 美元開盤，市值為 10.7 億美元</p>

<p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) was upgraded by stock analysts at Barclays to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Pacira BioSciences（納斯達克股票代碼：PCRX - 獲取免費報告）在週一向投資者發佈的研究報告中被巴克萊的股票分析師上調至 “持有” 評級，Zacks.com 報道。</p>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pacira BioSciences</strong> 的提醒：</p>
</div><p>PCRX has been the topic of a number of other reports. Wall Street Zen upgraded shares of Pacira BioSciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Monday, November 17th. Truist Financial lowered their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Pacira BioSciences in a report on Monday. Finally, Zacks Research raised Pacira BioSciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average target price of $28.20.</p>
<div class="lb-trans"><p>PCRX 已成為其他多份報告的主題。華爾街禪在 11 月 8 日的研究報告中將 Pacira BioSciences 的股票評級從 “買入” 上調至 “強力買入”。HC Wainwright 在 11 月 17 日的報告中重申了 “買入” 評級，並對 Pacira BioSciences 的股票設定了 38.00 美元的目標價。Truist Financial 在 11 月 7 日的研究報告中將 Pacira BioSciences 的股票目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “買入” 評級。Weiss Ratings 在週一的報告中重申了 Pacira BioSciences 的 “賣出（d+）” 評級。最後，Zacks Research 在 8 月 14 日的研究報告中將 Pacira BioSciences 的評級從 “強烈賣出” 上調至 “持有”。三位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價為 28.20 美元。</p>
</div><p><strong>View Our Latest Stock Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Pacira BioSciences 股票報告</strong></p>
</div><h2>Pacira BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股票表現</h2>
</div><p>Shares of NASDAQ:PCRX opened at $24.77 on Monday. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. Pacira BioSciences has a 1-year low of $18.17 and a 1-year high of $27.64. The stock has a market capitalization of $1.07 billion, a P/E ratio of 55.05 and a beta of 0.23. The business has a 50-day moving average price of $23.09 and a two-hundred day moving average price of $24.13.</p>
<div class="lb-trans"><p>納斯達克股票代碼：PCRX 的股票在週一開盤價為 24.77 美元。該公司的流動比率為 5.26，速動比率為 3.78，債務與股本比率為 0.52。Pacira BioSciences 的 1 年最低價為 18.17 美元，1 年最高價為 27.64 美元。該股票的市值為 10.7 億美元，市盈率為 55.05，貝塔值為 0.23。該公司的 50 日移動平均價格為 23.09 美元，200 日移動平均價格為 24.13 美元。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a net margin of 2.99% and a return on equity of 12.82%. The company had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. During the same quarter last year, the firm earned $0.79 EPS. The company's revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts predict that Pacira BioSciences will post 2.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（納斯達克股票代碼：PCRX - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.70 美元，超出市場共識預期的 0.65 美元，超出幅度為 0.05 美元。Pacira BioSciences 的淨利潤率為 2.99%，股本回報率為 12.82%。該公司本季度的收入為 1.7952 億美元，而分析師預期為 1.8286 億美元。去年同期，該公司每股收益為 0.79 美元。該公司的季度收入同比增長 6.5%。股票分析師預測 Pacira BioSciences 在本年度將發佈 2.41 美元的每股收益。</p>
</div><h2>Insider Transactions at Pacira BioSciences</h2>
<div class="lb-trans"><h2>Pacira BioSciences 的內部交易</h2>
</div><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 3,960 shares of Pacira BioSciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $24.09, for a total value of $95,396.40. Following the sale, the insider owned 178,367 shares of the company's stock, valued at $4,296,861.03. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Pacira BioSciences 的新聞中，內部人士 Jonathan Slonin 在 11 月 17 日的交易中出售了 3,960 股 Pacira BioSciences 的股票。該股票以平均價格 24.09 美元出售，總價值為 95,396.40 美元。出售後，該內部人士持有該公司 178,367 股股票，價值為 4,296,861.03 美元。此交易代表其持股比例下降了 2.17%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。公司內部人士持有該公司 6.40% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Pacira BioSciences</h2>
<div class="lb-trans"><h2>機構投資者對 Pacira BioSciences 的看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in shares of Pacira BioSciences during the 1st quarter worth approximately $32,506,000. Doma Perpetual Capital Management LLC lifted its position in shares of Pacira BioSciences by 49.7% in the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock worth $69,613,000 after purchasing an additional 897,255 shares in the last quarter. Balyasny Asset Management L.P. boosted its holdings in Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock worth $50,925,000 after purchasing an additional 565,288 shares during the last quarter. American Century Companies Inc. grew its position in Pacira BioSciences by 392.2% in the first quarter. American Century Companies Inc. now owns 667,423 shares of the company's stock valued at $16,585,000 after purchasing an additional 531,831 shares in the last quarter. Finally, Nuveen LLC bought a new position in Pacira BioSciences in the first quarter valued at $12,884,000. Institutional investors own 99.73% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。Alyeska Investment Group L.P.在第一季度購買了 Pacira BioSciences 的新頭寸，金額約為 32,506,000 美元。Doma Perpetual Capital Management LLC 在第三季度將其在 Pacira BioSciences 的持倉提高了 49.7%。Doma Perpetual Capital Management LLC 現在擁有該公司 2,701,324 股股票，價值 69,613,000 美元，此前在上個季度又購買了 897,255 股。Balyasny Asset Management L.P.在第二季度將其在 Pacira BioSciences 的持倉提高了 36.1%。Balyasny Asset Management L.P.現在擁有該公司 2,130,733 股股票，價值 50,925,000 美元，此前在上個季度又購買了 565,288 股。American Century Companies Inc.在第一季度將其在 Pacira BioSciences 的持倉提高了 392.2%。American Century Companies Inc.現在擁有該公司 667,423 股股票，價值 16,585,000 美元，此前在上個季度又購買了 531,831 股。最後，Nuveen LLC 在第一季度購買了 Pacira BioSciences 的新頭寸，價值為 12,884,000 美元。機構投資者持有該公司 99.73% 的股票。</p>
</div><h2>Pacira BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.</p>
<div class="lb-trans"><p>Pacira Biosciences, Inc 是一家控股公司，專注於提供非阿片類疼痛管理和再生健康解決方案，以改善患者在神經疼痛路徑上的體驗。其產品包括 EXPAREL、iovera 和 DepoFoam。該公司成立於 2006 年 12 月，總部位於佛羅里達州坦帕。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Pacira BioSciences</li>
<li>如何交易便士股票：逐步指南</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>3 只家居改善股票可以升級你的投資組合</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年爆發</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>安海斯 - 布希收購 BeatBox 以贏得年輕飲酒者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pacira BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Pacira BioSciences 嗎？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Pacira BioSciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Pacira BioSciences 並不在名單上。</p>
</div><p>While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Pacira BioSciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Pacira BioSciences（納斯達克代碼：PCRX）在巴克萊的評級被上調至持有